Huntington's Disease: From Somatic CAG Expansion to Exon 1A and Huntington Lowering Therapies

In a Royal Society lecture, the speaker traces Huntington's disease from its genetic map on chromosome 4 to the latest therapeutic strategies. The talk highlights how mouse models, especially the R6 transgenic lines and knock-in Q150 mice, revealed key pathology such as nuclear inclusions, amyloid-like aggregates, and transcriptional dysregulation. A central theme is the discovery of Huntington 1A, a small exon 1 transcript produced via cryptic intron 1 polyadenylation, whose protein product drives aggregation. The speaker discusses somatic CAG repeat expansion in neurons as a major disease driver and how recent preclinical and clinical studies are testing Huntington lowering approaches that target both Huntington 1A and full-length Huntington. The talk ends with exciting clinical data suggesting disease modification is possible.

Overview and historical context

The talk begins with Huntington's disease as an autosomal dominant neurodegenerative disorder characterized by movement, psychiatric, and cognitive symptoms. The disease is linked to a CAG repeat expansion in the huntingtin (HTT) gene, located on chromosome 4, with longer repeats correlating with earlier onset. The speaker emphasizes that a large portion of disease variation in onset is not explained by repeat length alone, pointing to other genetic and cellular factors that modify disease risk and progression.

Gene discovery, structure, and early models

The HTT gene was mapped in 1983, cloned a decade later, and found to encode a large scaffold protein with 67 exons. The mutation introduces a polyglutamine tract encoded by the CAG repeat in exon 1. Early work using R6 transgenic mice (human exon 1 HTT with expanded CAG repeats) revealed nuclear inclusion bodies and amyloid-like aggregates, as well as broad transcriptional dysregulation. These mouse models showed time-dependent disease phenotypes, facilitating numerous mechanistic studies and serving as a foundation for subsequent experiments.

Huntingtin 1A and intron 1 cryptic polyadenylation

Crucially, later work uncovered a second HTT transcript, Huntington 1A, produced by cryptic polyadenylation within intron 1 when a large CAG expansion is present. Huntington 1A encodes a small exon 1 derived protein that is highly aggregation-prone and pathogenic. The presentation details how HTT exon 1 transcripts can also arise from cryptic transcription termination, and how Huntington 1A protein accumulates and contributes to neuronal dysfunction and aggregation, with clear evidence from mouse models and increasingly from human-derived cells.

Somatic CAG expansion and genetic modifiers

The speaker explains that somatic CAG repeat expansion in brain tissue, particularly within medium spiny neurons, correlates with disease progression. Genetic modifiers, especially mismatch repair genes such as MSH2 and others, influence somatic instability and age at onset. This segment connects somatic instability to the broader pathogenic cascade, positioning somatic expansion as a critical driver of disease in the brain and a potential therapeutic target.

Pathogenic cascade and transcript/protein dynamics

A model is presented in which the mutant HTT allele increases Huntington 1A transcript production as the CAG repeat expands in brain, while full-length HTT protein levels decline in cells with very long repeats. Huntington 1A polyglutamine-containing protein promotes nuclear aggregation, which in turn disrupts transcription and triggers downstream cellular dysfunction. The data from knock-in HTT mice and human cell models support a two-pronged cascade: somatic expansion drives Huntington 1A production and aggregation, which then leads to transcriptional dysregulation and cellular pathology.

Therapeutic strategies and preclinical evidence

The talk surveys Huntington lowering strategies that aim to reduce both Huntington 1A and full-length Huntington transcripts. Preclinical data from mouse studies using antisense oligonucleotides (ASOs) and RNA interference (RNAi) demonstrate that lowering Huntington 1A, in combination with full-length HTT suppression, yields reductions in aggregation and partial rescue of transcriptional dysregulation. In some preclinical settings, Huntington 1A targeting alone can have substantial effects on aggregation and disease markers, though combinatorial approaches may be more effective in models with long baseline repeats.

Clinical translation and current trials

The talk highlights clinical translation, including the Tominersen (IONIS-HTT-Rx) ASO trial that targeted total HTT and encountered safety concerns with modest efficacy. New data from preclinical studies and early human trials point toward strategies that selectively target Huntington 1A and full-length HTT or utilize DIV-SIRNA approaches to achieve durable HTT suppression in the CNS. A leading example from Unicure using AMT 130 delivered through convection enhanced delivery shows disease-modifying potential with substantial slowing of progression and biomarker changes, marking a significant milestone in Huntington's disease therapy. The speaker underscores the importance of understanding the relative contributions of Huntington 1A and full-length HTT for designing effective, accessible treatments for all patients.

Future directions and closing thoughts

Looking ahead, the speaker calls for continued exploration of somatic expansion as a therapeutic target, further dissection of Huntington 1A biology, and development of strategies that can be delivered safely and widely. Collaboration with clinical networks and supportive funding bodies like CHDI are highlighted as essential to translating mechanistic insights into accessible therapies. The lecture ends with appreciation for the community and the ongoing effort to bring effective disease-modifying treatments to patients.